انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Feline Diabetes: SGLT2 Inhibitor FAQs with Dr. Mott
Manage episode 454012669 series 2641903
When a new drug class enters the veterinary world, first comes the excitement…then comes the learning. In this episode of Clinician’s Brief Partner Podcast, Jocelyn Mott, DVM, DACVIM, answers your most frequently asked questions when it comes to using a novel drug class in the treatment of feline diabetes mellitus: the sodium-glucose cotransporter-2 inhibitor. Tune in as she explains when, how, and why to consider this option in newly diagnosed feline diabetics.
Sponsored by Elanco
Resource:
Contact us:
- Podcast@briefmedia.com
Where to find us:
- Cliniciansbrief.com/podcasts
- Facebook.com/clinciansbrief
- Twitter: @cliniciansbrief
- Instagram: @clinicians.brief
The Team:
- Beth Molleson, DVM - Host
- Taylor Argo - Producer & Project Manager, Brief Studio
- Randall Stupka - Podcast Production & Sound Editing
293 حلقات
Manage episode 454012669 series 2641903
When a new drug class enters the veterinary world, first comes the excitement…then comes the learning. In this episode of Clinician’s Brief Partner Podcast, Jocelyn Mott, DVM, DACVIM, answers your most frequently asked questions when it comes to using a novel drug class in the treatment of feline diabetes mellitus: the sodium-glucose cotransporter-2 inhibitor. Tune in as she explains when, how, and why to consider this option in newly diagnosed feline diabetics.
Sponsored by Elanco
Resource:
Contact us:
- Podcast@briefmedia.com
Where to find us:
- Cliniciansbrief.com/podcasts
- Facebook.com/clinciansbrief
- Twitter: @cliniciansbrief
- Instagram: @clinicians.brief
The Team:
- Beth Molleson, DVM - Host
- Taylor Argo - Producer & Project Manager, Brief Studio
- Randall Stupka - Podcast Production & Sound Editing
293 حلقات
كل الحلقات
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.